We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Allergan Plc | LSE:0Y7T | London | Ordinary Share | IE00BY9D5467 | ALLERGAN ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 154.21 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDM0Y7T
RNS Number : 5053M
J.P. Morgan Securities LLC
11 May 2020
Ap27
FORM 38.5(b) IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY 1. KEY INFORMATION Name of exempt principal J.P Morgan Securities LLC trader Company dealt in Allergan plc ========================= Class of relevant security Ordinary Share to which the dealings being disclosed relate (Note 1) ========================= Date of dealing 8 May 2020 ========================= 2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant
security dealt in (Note 2) Long Short Number (%) Number (%) ========= ====== =========== ====== 10,400,644 3,406,704 (1) Relevant securities 3.16 1.03 ================= =================== (2) Derivatives (other 4,225,421 than options) 4,086,479 1.24 1.28 ================= =================== (3) Options and agreements to purchase/sell 305,000 0.09 0 0.00 ================= =================== 14,792,123 7,632,125 Total 4.49 2.31 ================= ===================
(b) Interests and short positions in relevant securities of the company, other than the class dealt
in (Note 2) Class of relevant security: Long Short Number (%) Number (%) ========= ====== =========== ====== (1) Relevant securities =================== ===================== (2) Derivatives (other than options) =================== ===================== (3) Options and agreements to purchase/sell =================== ===================== Total =================== =====================
Ap28
3. DEALINGS (Note 3) (a) Purchases and sales Purchase/sale Number of relevant securities Price per unit (Note 4) Purchases 4,309,711 192.1350 USD 200 192.3100 USD 23 192.5900 USD 1 192.6600 USD 206 192.8354 USD 500 192.8580 USD 526 192.9900 USD 500 192.9950 USD 41,748 193.0094 USD 884 193.0100 USD 1,849,037 193.0200 USD 400 193.0550 USD 100 193.1100 USD Sales 1 192.1000 USD 400 192.3100 USD 800 192.3750 USD 1,765 192.3978 USD 31 192.4100 USD 15 192.4433 USD 100 192.4600 USD 300 192.4667 USD 20 192.4710 USD 1,892 192.5100 USD 2 192.6350 USD 1 192.6600 USD 5 192.6700 USD 7 192.7057 USD 3 192.7100 USD 2 192.7350 USD 1 192.7400 USD 26 192.9900 USD 500 192.9950 USD 70,356 193.0200 USD 600 193.5002 USD 106 193.5006 USD ==================================== =================== (b) Derivatives transactions (other than options transactions) Product Nature of transaction Number of relevant Price per name, securities unit e.g. CFD (Note 5) (Note 6) (USD) (Note 4) Equity Swaps Long 200 192.3100 7,229 193.0200 Short 500 192.9950 ====================== =================== ========== (c) Options transactions in respect of existing relevant securities (i) Writing, selling, purchasing or varying Product Writing, Number of Exercise Type, Expiry Option name, selling, securities price e.g. American, date money paid/received e.g. call purchasing, to which European per unit option varying the option etc. (Note 4) etc. relates (Note 7) (ii) Exercising Product name, Number of securities Exercise price e.g. call option per unit (Note 4)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Nature of transaction Details Price per unit (Note 7) (if applicable) (Note 4)
Ap29
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and
any other person relating to the voting rights of any relevant securities under any
option referred to
on this form or relating to the voting rights or future acquisition or disposal of any relevant securities
to which any derivative referred to on this form is referenced. If none, this should be stated.
Is a Supplemental Form 38.5(b) attached? (Note 8) YES Date of disclosure 11 May 2020 Contact name Alwyn Basch ============================= Telephone number 020 7742 7407 ============================= Name of offeree/offeror Allergan plc with which connected ============================= Nature of connection (Note Financial Advisor to Allergan 9) plc =============================
Ap31
SUPPLEMENTAL FORM 38.5(b) IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DETAILS OF OPEN POSITIONS (This form should be attached to Form 38.5(b)) OPEN POSITIONS (Note 1) Product Written Number of Exercise Type, e.g. Expiry name, or purchased relevant price American, date e.g. call securities (Note European option to which 2) etc. the option or derivative relates Put Option Written 300,000 150.00 American 19JUN20 Put Option Written 5,000 140.00 American 19JUN20 ============== =============== ========= =========== ========
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated. For full details of disclosur e requirements, see Rules 8 and
38.5 of the Rules. If in doubt, consult the Panel.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ISEKZGMKGMGGGZM
(END) Dow Jones Newswires
May 11, 2020 06:52 ET (10:52 GMT)
1 Year Allergan Chart |
1 Month Allergan Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions